Site-specific Response to Nivolumab in Renal Cell Carcinoma.

Anticancer research 2021 Mar

filter terms:

Nivolumab monotherapy for advanced/metastatic renal cell carcinoma (RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses to nivolumab in various metastatic and primary sites in patients with RCC. We retrospectively reviewed 68 patients who underwent nivolumab monotherapy after one or more regimens of targeted therapy for advanced/metastatic RCC. The site-specific response was evaluated and progression-free survival was estimated. The site-specific overall response rates (ORRs) were as follows: lung (36%), bone (5%), lymph node (33%), liver (50%), adrenal gland (29%), pancreas (33%), and brain (0%). The ORR of bone metastasis was significantly worse in comparison to lung and liver metastases (p=0.017, 0.008). The site-specific median progression-free survival times were as follows: lung (5.1 months), bone (not reached), lymph node (not reached), and liver (17.5 months). Responses to nivolumab may vary depending on metastasized organs. Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Citation

Takahito Negishi, Nobuki Furubayashi, Tohru Nakagawa, Naotaka Nishiyama, Hiroshi Kitamura, Yoshifumi Hori, Kentarou Kuroiwa, Yuhyon Son, Narihito Seki, Toshihisa Tomoda, Eijiro Okajima, Motonobu Nakamura. Site-specific Response to Nivolumab in Renal Cell Carcinoma. Anticancer research. 2021 Mar;41(3):1539-1545